The absolute quantification of eight inter-α-trypsin inhibitor heavy chain 4 (ITIH4)-derived peptides in serum from breast cancer patients

Proteomics - Clinical Applications

Volumn 4, Issue 12, 2010, Pages 931-939

  Van Den Broek, Irene ^a   Sparidans, Rolf W ^a   Van Winden, Annemieke W J ^b,c   Gast, Marie Christine W ^b   Van Dulken, Eric J ^b   Schellens, Jan H M ^a,d   Beijnen, Jos H ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Breast cancer; ITIH4; LC MS MS; Quantification; Serum

Indexed keywords

INTER ALPHA TRYPSIN INHIBITOR; INTER ALPHA TRYPSIN INHIBITOR HEAVY CHAIN 4; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-GLOBULINS; BLOOD PROTEINS; BREAST NEOPLASMS; CHROMATOGRAPHY, LIQUID; FEMALE; GLYCOPROTEINS; HUMANS; MIDDLE AGED; NEOPLASMS; PEPTIDE FRAGMENTS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; SPECIMEN HANDLING; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 78649710819     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201000035     Document Type: Article

References (35)

1. Duffy, M. J., Serum tumor markers in breast cancer: are they of clinical value? Clin. Chem. 2006, 52, 345-351.
2. Harris, L., Fritsche, H., Mennel, R., Norton, L. et al., American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 2007, 25, 5287-5312.
3. Caputo, E., Lombardi, M. L., Luongo, V., Moharram, R. et al., Peptide profiling in epithelial tumor plasma by the emerging proteomic techniques. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2005, 819, 59-66.
4. Fung, E. T., Yip, T. T., Lomas, L., Wang, Z. et al., Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int. J. Cancer 2005, 115, 783-789.
5. Gast, M. C., Van Gils, C. H., Wessels, L. F., Harris, N. et al., Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS. Oncol. Rep. 2009, 22, 205-213.
6. Koomen, J. M., Shih, L. N., Coombes, K. R., Li, D. et al., Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin. Cancer Res. 2005, 11, 1110-1118.
7. Song, J., Patel, M., Rosenzweig, C. N., Chan-Li, Y. et al., Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay. Clin. Chem. 2006, 52, 1045-1053.
8. Villanueva, J., Shaffer, D. R., Philip, J., Chaparro, C. A. et al., Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 2006, 116, 271-284.
9. Koomen, J. M., Li, D., Xiao, L. C., Liu, T. C. et al., Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J. Proteome Res. 2005, 4, 972-981.
10. Mohri, Y., Mohri, T., Wei, W., Qi, Y. J. et al., Identification of macrophage migration inhibitory factor and human neutrophil peptides 1-3 as potential biomarkers for gastric cancer. Br. J. Cancer 2009, 101, 295-302.
11. Pietrowska, M., Marczak, L., Polanska, J., Behrendt, K. et al., Mass spectrometry-based serum proteome pattern analysis in molecular diagnostics of early stage breast cancer. J. Transl. Med. 2009, 7, 60.
12. van Winden, A. C. J., van den Broek, I., Gast, M. C. W., Engwegen, J. Y. M. N. et al., Serum degradome markers for the detection of breast cancer. J. Proteome Res. 2010, 9, 3781-3788.
13. Zhang, Z., Bast R. C., Jr., Yu, Y., Li, J. et al., Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004, 64, 5882-5890.
14. Choi-Miura, N. H., Sano, Y., Oda, E., Nakano, Y. et al., Purification and characterization of a novel glycoprotein which has significant homology to heavy chains of inter-alpha-trypsin inhibitor family from human plasma. J. Biochem. 1995, 117, 400-407.
15. Nishimura, H., Kakizaki, I., Muta, T., Sasaki, N. et al., cDNA and deduced amino acid sequence of human PK-120, a plasma kallikrein-sensitive glycoprotein. FEBS Lett. 1995, 357, 207-211.
16. Choi-Miura, N. H., Quantitative measurement of the novel human plasma protein, IHRP, by sandwich ELISA. Biol. Pharm. Bull. 2001, 24, 214-217.
17. Pineiro, M., Alava, M. A., Gonzalez-Ramon, N., Osada, J. et al., ITIH4 serum concentration increases during acute-phase processes in human patients and is up-regulated by interleukin-6 in hepatocarcinoma HepG2 cells. Biochem. Biophys. Res. Commun. 1999, 263, 224-229.
18. Kashyap, R. S., Nayak, A. R., Deshpande, P. S., Kabra, D. et al., Inter-alpha-trypsin inhibitor heavy chain 4 is a novel marker of acute ischemic stroke. Clin. Chim. Acta 2009, 402, 160-163.
19. Pu, X. P., Iwamoto, A., Nishimura, H., Nagasawa, S., Purification and characterization of a novel substrate for plasma kallikrein (PK-120) in human plasma. Biochim. Biophys. Acta 1994, 1208, 338-343.
20. Hsieh, S. Y., Chen, R. K., Pan, Y. H., Lee, H. L., Systematical evaluation of the effects of sample collection procedures on low-molecular-weight serum/plasma proteome profiling. Proteomics 2006, 6, 3189-3198.
21. Villanueva, J., Philip, J., Chaparro, C. A., Li, Y. et al., Correcting common errors in identifying cancer-specific serum peptide signatures. J. Proteome Res. 2005, 4, 1060-1072.
22. West-Nielsen, M., Hogdall, E. V., Marchiori, E., Hogdall, C. K. et al., Sample handling for mass spectrometric proteomic investigations of human sera. Anal. Chem. 2005, 77, 5114-5123.
23. Davis, M. T., Auger, P., Spahr, C., Patterson, S. D., Cancer biomarker discovery via low molecular weight serum proteome profiling - where is the tumor? Proteomics Clin. Appl. 2007, 1, 1545-1558.
24. Diamandis, E. P., Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J. Natl. Cancer Inst. 2004, 96, 353-356.
25. van den Broek, I., Sparidans, R. W., Schellens, J. H., Beijnen, J. H., Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2008, 872, 1-22.
26. 4-derived putative biomarker peptides in clinical serum samples. Rapid Commun. Mass Spectrom. 2010, 24, 1842-1850.
27. Guidance for Industry: Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CEDR), Center for Veterinary Medicine (CVM), BP, May 2001.
28. Barnidge, D. R., Goodmanson, M. K., Klee, G. G., Muddiman, D. C., Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-MS/MS using protein cleavage and isotope dilution mass spectrometry. J. Proteome Res. 2004, 3, 644-652.
29. Barr, J. R., Maggio, V. L., Patterson, D. G., Jr., Cooper, G. R. et al., Isotope dilution - mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I. Clin. Chem. 1996, 42, 1676-1682.
30. Kuhn, E., Wu, J., Karl, J., Liao, H. et al., Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics 2004, 4, 1175-1186.
31. van den Broek, I., Sparidans, R. W., Schellens, J. H., Beijnen, J. H., Liquid chromatography/tandem mass spectrometric method for the quantification of eight proteolytic fragments of ITIH4 with biomarker potential in human plasma and serum. Rapid Commun Mass Spectrom 2008, 22, 2915-2928.
32. Gast, M. C., van Gils, C. H., Wessels, L. F., Harris, N. et al., Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS). Clin. Chem. Lab. Med. 2009, 47, 694-705.
33. Engwegen, J. Y. M. N., Alberts, M., Knol, J. C., Jimenez, C. R. et al., Influence of variations in sample handling on SELDI-TOF MS serum protein profiles for colorectal cancer. Proteomics Clin. Appl. 2008, 2, 936-945.
34. Timms, J. F., Arslan-Low, E., Gentry-Maharaj, A., Luo, Z. et al., Preanalytic influence of sample handling on SELDI-TOF serum protein profiles. Clin. Chem. 2007, 53, 645-656.
35. van den Broek, I., Sparidans, R. W., Schellens, J. H., Beijnen, J. H., Specific investigation of sample handling effects on protease activities and absolute serum concentrations of various putative peptidome markers. Clin. Proteomics 2010, in press.